Amgen focuses on migraine launch as growth remains slow

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 11:12 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via
    • Amgen Inc.'s first quarter 2018 revenue increased 2% from the year-prior quarter to $5.6 billion. Net income came in 12% higher at $2.3 billion.
    • New and recent launches, including Repatha (evolocumab), Kyprolis (carfilzomib), Prolia (denosumab) and Xgeva (denosumab) have shown double-digit growth.

    article source